Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Robelin P, Tod M, Colomban O, Lachuer J, Ray-Coquard I, Rauglaudre G, Joly F, Chevalier-Place A, Combe P, Lortholary A, Hamizi S, Raban N, Ferron G, Meunier J, Berton-Rigaud D, Alexandre J, Kaminsky MC, Dubot C, Leary A, Malaurie E, You B. Robelin P, et al. Among authors: alexandre j. Gynecol Oncol. 2020 Oct;159(1):256-263. doi: 10.1016/j.ygyno.2020.07.021. Epub 2020 Jul 22. Gynecol Oncol. 2020. PMID: 32712155 Clinical Trial.
[Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].
Ray-Coquard I, Pautier P, Pujade-Lauraine E, Méeus P, Morice P, Treilleux I, Duvillard P, Alexandre J, Lhommé C, Selle F, Guastalla J. Ray-Coquard I, et al. Among authors: alexandre j. Bull Cancer. 2010 Jan;97(1):123-35. doi: 10.1684/bdc.2010.1017. Bull Cancer. 2010. PMID: 20007069 Free article. French.
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).
Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E; GINECO group France. Lortholary A, et al. Among authors: alexandre j. Ann Oncol. 2012 Feb;23(2):346-52. doi: 10.1093/annonc/mdr149. Epub 2011 May 11. Ann Oncol. 2012. PMID: 21562072 Free article. Clinical Trial.
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.
Trédan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I. Trédan O, et al. Among authors: alexandre j. Target Oncol. 2013 Dec;8(4):243-51. doi: 10.1007/s11523-012-0242-9. Epub 2012 Dec 13. Target Oncol. 2013. PMID: 23238879 Clinical Trial.
A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.
Weber B, Largillier R, Ray-Coquard I, Yazbek G, Meunier J, Alexandre J, Dauba J, Spaeth D, Delva R, Joly F, Pujade-Lauraine E, Copel L; GINECO group, France. Weber B, et al. Among authors: alexandre j. Support Care Cancer. 2013 Jul;21(7):1947-54. doi: 10.1007/s00520-013-1748-0. Epub 2013 Feb 19. Support Care Cancer. 2013. PMID: 23420555 Clinical Trial.
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.
Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, Pujade-Laurraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A. Maillet D, et al. Among authors: alexandre j. Gynecol Oncol. 2014 Jan;132(1):181-7. doi: 10.1016/j.ygyno.2013.10.013. Epub 2013 Oct 22. Gynecol Oncol. 2014. PMID: 24157616
777 results